Equities
Health CareMedical Equipment and Services
  • Price (SEK)188.35
  • Today's Change1.05 / 0.56%
  • Shares traded351.52k
  • 1 Year change-1.59%
  • Beta0.9179
Data delayed at least 15 minutes, as of Jul 14 2025 17:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Getinge AB is a Sweden-based company operating within healthcare sector. The Company provides hospitals and Life Science institutions with products and solutions aimed at improving clinical outcomes and optimizing workflows. The Company’s reporting segments have the following activities: Acute Care Therapies develops solutions for life-sustaining care in acute health conditions. Life Science offers a comprehensive range of equipment, technical expertise and prevention consultation contamination in pharmaceutical production, biomedical research, production of medical equipment and in various laboratory applications. Surgical Workflows offers products and services for the effective disinfection and sterilization of instruments used in operations, operating tables and others hardware for operating rooms and advanced IT systems for efficient and secure workflows in hospitals.

  • Revenue in SEK (TTM)35.57bn
  • Net income in SEK1.48bn
  • Incorporated1990
  • Employees11.83k
  • Location
    Getinge ABLindholmspiren 7,P.O. Box 8861GOETEBORG 417 56SwedenSWE
  • Phone+46 35155500
  • Fax+46 8295532
  • Websitehttps://www.getinge.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
GETI B:STO since
announced
Transaction
value
Paragonix Technologies IncDeal completed22 Aug 202422 Aug 2024Deal completed-7.40%477.00m
Data delayed at least 15 minutes, as of Jul 14 2025 17:00 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
RaySearch Laboratories AB (publ)1.27bn223.62m9.96bn422.0053.3812.9422.857.876.526.5236.9326.890.61448.173.143,044,546.0010.852.9616.364.3791.8890.9317.665.801.52217.600.327767.9016.629.96149.4932.190.5132--
Biotage AB1.96bn255.00m11.43bn622.0044.872.9726.285.833.183.1824.4848.050.3981.667.442,913,819.005.188.475.869.9362.6261.6213.0015.071.5624.710.058348.019.8313.3015.458.7430.04--
ChemoMetec A/S688.27m253.24m14.02bn184.0055.3715.6649.9220.379.729.7226.4134.360.69430.73156.342,656,324.0025.5527.9630.4335.1080.0679.5736.7935.022.92--0.0128144.08-8.2218.37-23.7226.649.97-11.81
Elekta AB (publ)18.02bn237.00m17.68bn4.54k77.262.0811.490.98120.62070.620747.1523.040.59673.733.053,972,002.000.79153.481.416.2137.8038.221.336.020.863413.350.46192.20-0.56854.29-81.80-26.2215.565.92
Vitrolife AB3.61bn498.00m19.83bn1.15k39.841.5121.075.493.673.6726.6396.910.21543.645.973,222,322.002.97-3.383.08-3.5259.3258.0613.80-17.403.088.140.1294--2.7619.51113.326.0318.32--
Embla Medical hf8.20bn689.99m20.84bn4.08k30.222.7316.862.541.081.0812.7811.930.54752.146.691,342,645.004.643.775.484.4263.1962.228.476.601.104.850.39730.008.814.4916.940.66884.25--
AddLife AB10.42bn309.00m21.70bn2.25k72.614.3819.292.082.542.5485.4941.990.81383.915.794,617,908.002.434.453.647.0037.5837.392.995.130.52523.010.48333.596.2124.2132.6312.3828.288.45
Ambu A/S8.74bn554.16m33.87bn5.24k69.554.3421.143.881.381.3821.8422.200.80612.177.201,122,787.005.113.225.883.8760.2759.546.344.431.6739.600.085725.4112.9013.8439.88-5.812.060.00
Asker Healthcare Group AB-100.00bn-100.00bn41.09bn3.57k----------------------------------------1.06--0.3635--11.69--77.34------
Getinge AB35.57bn1.48bn47.60bn11.83k34.491.6713.101.345.435.43130.58112.170.61012.717.013,016,369.002.565.163.366.7947.5547.884.208.480.82917.570.271943.259.215.53-32.096.031.4225.12
Sectra AB2.07bn563.37m65.56bn1.30k123.0836.2197.1431.712.932.9310.749.950.593527.851.401,595,180.0016.1715.7530.6429.9250.0460.2927.2522.411.72--0.043610.0919.854.4731.5118.877.19--
Demant A/S33.58bn4.33bn84.41bn21.35k19.795.87--2.5113.3210.99103.2144.900.71181.995.901,050,120.009.188.8111.6013.1676.2374.7912.9012.321.226.070.61920.003.798.452.5214.610.1745--
Coloplast A/S41.63bn6.81bn188.96bn16.74k29.757.9821.464.5420.1720.17123.3975.180.57142.455.921,710,716.009.3416.2113.1722.9167.5267.8516.3521.020.60828.870.588992.2310.338.545.625.4614.305.29
Data as of Jul 14 2025. Currency figures normalised to Getinge AB's reporting currency: Swedish Krona SEK

Institutional shareholders

37.73%Per cent of shares held by top holders
HolderShares% Held
Fj�rde AP-fondenas of 31 Dec 202421.01m8.27%
AMF Fonder ABas of 21 Feb 202514.14m5.56%
Carnegie Fonder ABas of 31 Dec 202411.66m4.59%
Swedbank Robur Fonder ABas of 31 Dec 20249.66m3.80%
Incentive ASas of 31 Dec 20248.83m3.48%
The Vanguard Group, Inc.as of 02 Jul 20258.02m3.16%
Handelsbanken Fonder ABas of 30 Jun 20257.65m3.01%
Lannebo Kapitalf�rvaltning AB (Sweden)as of 31 Dec 20246.05m2.38%
Norges Bank Investment Managementas of 31 Dec 20245.62m2.21%
BlackRock Fund Advisorsas of 03 Jul 20253.23m1.27%
More ▼
Data from 31 Dec 2024 - 30 Jun 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.